Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Optical Guidewire Provides Reliable FFR Pressure Measurements

By HospiMedica International staff writers
Posted on 04 Apr 2016
A novel guidewire helps measure the severity of coronary stenosis in the treatment of patients with coronary artery disease (CAD).

The OptoWire II is a nitinol-based optical guidewire developed to measure fractional flow reserve (FFR) using patented optical pressure detection, optical contact, and optical coherence technologies providing a robust signal transmission that enables immediate and reliable connectivity and FFR measurement recovery under extended conditions of usage. More...
The guidewire is designed with a hydrophilic coating to improve its performance, and it is also immune to the many adverse effects related to blood contact.

The OptoWire II is also designed to provide cardiologists with a guidewire that can help them navigate tortuous coronary arteries and cross highly calcified blockages with ease and safety under different scenarios. This is achieved with the aid of the concentric wire construction, which provides enhanced torque control and steerability performance. The OptoWire II is a product of Opsens Medical (Quebec, Canada), and has been approved by the US Food and Drug Administration (FDA).

“The hydrophilic coating and the increased flexibility profile should facilitate the evaluation of complex coronary blockages, helping cardiologists in deciding on the most appropriate treatment,” said Claude Belleville, vice president of medical devices at Opsens Medical. “This ease of use could help to promote the use of the FFR and further expand access to this diagnostic that improves patient outcomes. We are committed to becoming the first choice of cardiologists, hence helping them to improve the clinical outcome of patients with coronary artery disease.”

FFR is a physiological index to determine the hemodynamic severity of intracoronary lesions. It can accurately identify lesions responsible for ischemia which, in many cases, would have been undetected or not correctly assessed by imaging technologies. Various clinical studies have demonstrated that lesion assessment by FFR to guide routine percutaneous coronary intervention (PCI) is superior to angiography guided treatment. FFR-guided treatment has also been shown to reduce costs due to lower procedural costs, reduced numbers of follow-ups for major adverse cardiac events, and shorter hospital stay.

Related Links:

Opsens Medical



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammography System (Analog)
MAM VENUS
Absorbable Monofilament Mesh
Phasix Mesh
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.